DIAGNOS Announces its Exclusive Strategic Partnership Agreement with Labtician Ophthalmics, a Leader in Canadian and Internat...
February 24 2021 - 9:30AM
Diagnos Inc. (“DIAGNOS” or “the Corporation”) (TSX Venture: ADK)
(OTCQB: DGNOF) a leader in early detection of critical health
issues through the use of its FLAIRE platform based on Artificial
Intelligence (AI), announces its exclusive strategic partnership
agreement with Labtician Ophthalmics (“Labtician”), a Toronto-based
company with customers across Canada who will introduce and
commercialize DIAGNOS AI platform to monitor ocular health and
improve patient care in diabetic patients. An initial agreement
with Labtician was announced on June 3rd, 2020.
In an effort to increase its footprint and
accelerate its growth, DIAGNOS has decided to work with
organizations that are active in similar markets. The formalization
of this strategic partnership with Labtician will have the net
effect of allowing access to new customers across Canada. DIAGNOS’
CARA solution allows close monitoring of the effects of medications
used in retinal microcirculation to help professionals in their
day-to-day screening of their patients.
“We are pleased to be working with DIAGNOS in
addressing growing needs in the monitoring of diabetic and
hypertensive patients. For over 60 years, we’ve been world leaders
in innovative eye care products, solutions, and resources for
eyecare professionals and their patients. Through our extensive
network, we commercialize our high-quality eyecare products as well
as those of our forward-thinking partner companies in Canada and
worldwide. We help companies through the complexities and nuances
of Canadian and international markets, from prelaunch assistance
and obtaining regulatory approval, to securing commercialization,
and distribution channels,” explains
Labtician President, Polydor
Strouthos.
“I am pleased to be working with the team at
Labtician. Labtician brings a high-level of expertise in the
Canadian healthcare marketplace. Our growth strategy is to create
partnerships in select countries thereby leveraging local
relationships to accelerate the adoption of DIAGNOS’ CARA AI
Platform. Labtician is the ideal partner due to their long history
of working closely with Canadian Optometric and Ophthalmology
professionals dedicated to treating the effects of diabetes on the
eyes and preventing vision loss,” explains DIAGNOS CEO,
André Larente.
Labtician worked with Prism Eye Institute, a CAN
Health Network partner, to gain insights in how to best utilize
this revolutionary screening technology in the Canadian market.
With these insights, Labtician was able to find ways to bring this
technology to Canadians using existing care models. The CAN Health
Network is focused on building an integrated market and supporting
Canadian companies scale.
“More retina screening means earlier
intervention, better care, and a massive savings to the system,”
said Dr. Ike Ahmed, world renowned
Ophthalmologist and Medical Director at Prism Eye Institute, who
has led the efforts as part of his commitment to the
CAN Health Network. “We are strong supporters
of the CAN Health Network and
helping world-class Canadian health tech companies
succeed. By supporting Canadian companies, our patient’s community
and economy all benefit.”
About Labtician With 60 years of history in
Canada, Labtician has evolved from a manufacturer of quality
ophthalmic products for the global market to a specialized
commercialization partner for the Canadian ophthalmic market. In
their capacity as a commercialization partner, they offer the
“complete Canadian solution.” Labtician is actively involved in the
entire commercialization process from pre-launch, to launch and
post-launch. This involves regulatory, market access, importation
and distribution as well as sales and marketing activities.
Internationally, they offer commercialization expertise through
global partners.About DIAGNOSDIAGNOS is a publicly traded Canadian
corporation dedicated to early detection of critical health
problems based of its FLAIRE Artificial Intelligence (AI) platform.
FLAIRE allows for quick modifying and developing of applications
such as CARA (Computer Assisted Retina Analysis). CARA’s AI-based
image enhancement algorithms provide sharper, clearer and
easier-to-analyze retinal images. CARA is a cost-effective tool for
real-time screening of large volumes of patients. CARA has been
cleared for commercialization by the following regulators: Health
Canada, the FDA (USA), CE (Europe), COFEPRIS (Mexico) and Saudi FDA
(Saudi Arabia).
Additional information is available at
www.diagnos.com and www.sedar.com
This press release contains forward-looking
information. We cannot guarantee that the forward-looking
information mentioned will prove to be accurate, as there may be a
significant discrepancy between actual results or future events and
those mentioned in this statement. DIAGNOS disclaims any intention
or obligation to publicly update or revise any forward-looking
information, whether as a result of new information, future events
or otherwise. The forward-looking information contained in this
press release is expressly covered by this caution.
Neither the TSX Venture Exchange nor its
Regulation Services Provider (as that term is defined in the
policies of the TSX Venture Exchange) accepts responsibility for
the adequacy or accuracy of this release.
For further information, please contact:
Mr. André Larente, President
DIAGNOS Inc.
Tel: 450-678-8882 ext. 224
alarente@diagnos.ca
Diagnos (TSXV:ADK)
Historical Stock Chart
From Jun 2024 to Jul 2024
Diagnos (TSXV:ADK)
Historical Stock Chart
From Jul 2023 to Jul 2024